Press release
Pulmonary Drug Delivery Devices Industry Growth Supported by Innovation in Inhalers and Nebulizers, Topping USD 105.70 Billion by 2036
Pulmonary Drug Delivery Devices Market
👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=873
Market Overview
Pulmonary Drug Delivery Devices are medical devices used for respiratory drug delivery that are used to directly deliver drugs into the respiratory tract for treatment and management of airway and lung diseases. These devices find application in hospitals, clinics, home care, surgical centers, and ambulatory centers. The market is divided into offerings such as inhalers, nebulizers, nasal drug delivery systems, insufflators and other pulmonary delivery technologies.
Pulmonary drug delivery has been applied in the management of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, PAH, IPF, and for systemic drug delivery. Drug delivery is a complex procedure involving aerosol production, breathing, lung deposition, dose delivery, and patient compliance monitoring. Increasing demand for inhalers, nebulizers and respiratory drug delivery systems, smart inhalers, home care respiratory, pulmonary therapeutics and others is anticipated to hold the potential opportunity for the market growth.
Analysts' Viewpoint
The market for pulmonary drug delivery devices is segregating into a large, competitive inhaler market for established respiratory drugs and a niche, high-value emerging market for the pulmonary delivery of complex biologics and new therapeutics. Producers of inhalers that form pulmonary delivery alliances with biotechs working on non-respiratory indications will find new growth beyond the traditional asthma and COPD markets," say analysts at Transparency Market Research.
Analysis of Key Players
Product innovation, strategic collaborations, acquisitions, and expansion of respiratory care portfolios characterize the competitive landscape.
Leading companies operating in the global pulmonary drug delivery devices market include:
• AstraZeneca Plc
• GlaxoSmithKline Plc (GSK)
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Cipla Ltd.
• 3M Company (Kindeva Drug Delivery)
• Koninklijke Philips N.V. (Philips Respironics)
• PARI Medical Holding GmbH
• Novartis AG
• Sunovion Pharmaceuticals Inc.
• MannKind Corporation
• Adherium Ltd.
• Propeller Health (ResMed)
• Omron Healthcare Co. Ltd.
• Vectura Group Plc (Philip Morris International)
Strategic investments in smart inhalers, connected respiratory monitoring devices, digital therapeutics, and next-generation inhalation technologies remain key competitive strategies among market participants.
Recent Developments (2025-2026)
• In April 2026, AstraZeneca received U.S. FDA approval for Breztri Aerosphere as a maintenance treatment for asthma in patients aged 12 years and older. The company stated that Breztri became the first and only single-inhaler triple therapy approved in the U.S. for asthma, expanding its use beyond chronic obstructive pulmonary disease.
• In May 2026, Teva Pharmaceuticals USA launched Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, a generic equivalent of Symbicort Inhalation Aerosol. The product was listed under Teva's recent product launches with a launch date of May 27, 2026.
• In May 2026, MannKind Corporation announced U.S. FDA approval of Afrezza for use in children and adolescents aged 6 years and older with diabetes. Afrezza is an inhaled mealtime insulin delivered through MannKind's Technosphere drug-delivery platform. The approval strengthens MannKind's pulmonary drug delivery portfolio and supports the use of inhaled therapies beyond traditional respiratory disease treatment.
👉 Discuss Implications for Your Industry Request Sample Market Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=873
Key Developments & Trends
• Smart Inhaler Adoption: Growing integration of digital sensors and mobile health applications.
• Home Healthcare Expansion: Increasing demand for portable pulmonary drug delivery devices.
• Targeted Drug Delivery: Rising preference for localized treatment with improved efficacy.
• Biologic Inhalation Therapies: Growing research into inhalable biologics and advanced formulations.
• Connected Respiratory Care: Integration of AI, remote monitoring, and telehealth platforms.
Challenges
• High Cost of Advanced Devices: Smart inhalers and digital respiratory systems may increase treatment costs.
• Patient Compliance Issues: Incorrect inhaler techniques can reduce treatment effectiveness.
• Regulatory Requirements: Strict approval processes for combination drug-device products.
• Device Compatibility: Ensuring compatibility between inhalers and specific drug formulations remains challenging.
Opportunities
• Increasing Respiratory Disease Burden: Rising prevalence of asthma, COPD, and other chronic lung diseases.
• Technological Innovation: Development of AI-enabled and connected pulmonary drug delivery systems.
• Emerging Market Growth: Expanding healthcare infrastructure and access to respiratory therapies.
• Personalized Respiratory Medicine: Increasing focus on customized treatment approaches and precision healthcare.
Market Segmentation
By Device Type
• Inhalers
o Pressurized Metered Dose Inhalers (pMDIs)
o Dry Powder Inhalers (DPIs)
o Soft Mist Inhalers (SMIs)
• Nebulizers
o Jet Nebulizers
o Ultrasonic Nebulizers
o Mesh Nebulizers
• Nasal Drug Delivery Systems
• Insufflators & Others
By Technology
• Standard Inhalers
• Smart/Connected Inhalers
• Breath-Actuated Inhalers
• Digital Adherence Monitoring Platforms
By Indication
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Pulmonary Arterial Hypertension (PAH)
• Idiopathic Pulmonary Fibrosis (IPF)
• Systemic Drug Delivery
o Insulin
o Vaccines
By End User
• Hospitals & Clinics
• Home Care Settings
• Ambulatory Surgical Centers (ASCs)
By Geography
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Conclusion
The pulmonary drug delivery devices market is expected to experience robust growth through 2036, driven by rising prevalence of respiratory diseases, technological advancements in inhalation systems, and increasing adoption of smart respiratory care solutions. Innovations in digital inhalers, connected healthcare platforms, inhalable biologics, and home-based respiratory therapies will continue to reshape the industry. As healthcare providers increasingly emphasize patient-centric and precision respiratory care, pulmonary drug delivery devices will remain an essential component of modern respiratory disease management.
👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=873
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Drug Delivery Devices Industry Growth Supported by Innovation in Inhalers and Nebulizers, Topping USD 105.70 Billion by 2036 here
News-ID: 4577823 • Views: …
More Releases from Transparency Market Research
Articulated Robot Industry Trends Highlight AI-Driven Automation, Pushing Market …
The global articulated robot market was valued at USD 22.6 billion in 2025 and is projected to reach USD 57.3 billion by 2036, expanding at a CAGR of 8.8% from 2026 to 2036. The market growth is driven by increasing industrial automation, rising adoption of Industry 4.0 technologies, growing labor shortages in manufacturing, and expanding demand for high-precision robotic systems across automotive, electronics, healthcare, and logistics industries.
👉 Get sample market…
Adhesive Bandages Market to Reach USD 5.8 Billion by 2036, Driven by Rising Woun …
The global adhesive bandages market plays a vital role in the wound care industry by offering convenient and effective solutions for treating minor cuts, abrasions, burns, and surgical wounds. Adhesive bandages are widely used in hospitals, clinics, ambulatory care centers, and home healthcare settings to protect wounds from contamination while promoting faster healing. The market has evolved significantly with the introduction of advanced materials, antimicrobial coatings, waterproof designs, and skin-friendly…
Electric Fireplaces Market to Reach USD 5.39 Billion by 2036, Driven by Rising D …
The global electric fireplaces market is witnessing steady growth as consumers increasingly seek energy-efficient, low-maintenance, and aesthetically appealing heating solutions. Unlike conventional wood-burning or gas fireplaces, electric fireplaces operate without chimneys, vents, or direct fuel combustion, making them a cleaner and safer alternative for residential and commercial spaces. These products combine advanced flame simulation technologies with efficient heating systems to provide both comfort and decorative appeal. Growing awareness regarding sustainable…
Lipid Disorder Treatment Market Size to Reach USD 43.9 Billion by 2036, Growing …
The Lipid Disorder Treatment Market is witnessing steady growth due to the increasing prevalence of cardiovascular diseases, dyslipidemia, and cholesterol-related disorders worldwide. Lipid disorders, including high low-density lipoprotein (LDL) cholesterol, elevated triglycerides, and low high-density lipoprotein (HDL) cholesterol, significantly increase the risk of heart attack, stroke, and atherosclerosis. Effective lipid-lowering therapies have become a critical component of preventive cardiology and chronic disease management. The market includes statins, fibrates, bile acid…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.Â
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
